The latest update is out from Graft Polymer (UK) PLC ( (GB:SVNS) ).
Solvonis Therapeutics has entered into an arrangement agreement to acquire Awakn Life Sciences Corp, marking a strategic expansion in mental health therapeutics. The acquisition, valued at approximately £4.98 million, involves the exchange of Solvonis shares for Awakn’s shares and securities, pending regulatory and shareholder approvals. This acquisition is anticipated to strengthen Solvonis’ position in the UK biotechnology ecosystem, leveraging Awakn’s clinical pipeline and expertise in addiction and mental health therapies.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics PLC is a biotechnology company focused on co-developing therapeutics for mental health disorders. It aims to enhance its market position by expanding its therapeutic offerings in the mental health sector.
YTD Price Performance: -12.50%
Average Trading Volume: 17,321,193
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £4.02M
For detailed information about SVNS stock, go to TipRanks’ Stock Analysis page.